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Abstract
Background The loss of response to infliximab in
Crohn’s disease (CD) patients is currently a major clinical
problem. Recently, mean platelet volume (MPV) has been
proposed as a new biomarker of CD activity. Here, we
hypothesized that MPV may be used as cheap and efficient
biomarker of subclinical inflammation during 52-week
therapy in CD patients responding to infliximab induction
treatment.
Aims The aim of study was to establish whether MPV at
baseline and pre-infusion at week 14 are good predictors of
sustained response after week 14 in CD patients undergo-
ing 52-week infliximab therapy.
Methods A retrospective study of 30 adult CD patients
who underwent a 52-week course of treatment with
infliximab and achieved response at week 14 to induction
treatment was performed. The association between MPV,
baseline disease parameters and maintained clinical
response or remission during infliximab therapy was
assessed.
Results Higher MPV at week 14 was observed in CD
patients with sustained response to infliximab after week
14 than in patients with loss of response (p = 0.0019). In
patients with loss of response to maintenance infliximab
treatment, lower DMPV between baseline and week 14 was
calculated (p = 0.0003). MPV[ 10.3 fl at week 14 pre-
dicts sustained response with 67 % sensitivity and 80 %
specificity. DMPV between baseline and week 14[0.4 fl
predicts sustained response with 87 % sensitivity and 93 %
specificity.
Conclusion MPV at week 14 and DMPV between base-
line and week 14 are good predictors of sustained response
to infliximab maintenance treatment in CD patients.
Keywords Crohn’s disease  Infliximab  Mean platelet
volume  Prognosis  Treatment outcomes
Introduction
Crohn’s disease (CD) is an inflammatory bowel disease
(IBD) characterized by chronic, segmental granulomatous
inflammation with periods of exacerbations and remissions,
which may involve any part of the gastrointestinal (GI)
tract [1]. The pathogenesis of the intestinal lesions in CD is
not entirely understood. Elevated pro-inflammatory cyto-
kine levels, mainly tumor necrosis factor alpha (TNF-a),
have strong impact on the clinical manifestations and
inflammatory lesions in the intestinal wall. The main target
of IBD treatment is long-term remission. Attempts have
been made to find an effective treatment—biological
therapy using anti-TNF-a antibodies, such as infliximab or
adalimumab, is currently the most attractive form of
treatment [1, 2].
The target of the anti-TNF-a therapy is mucosal healing
and long-term clinical remission. Unfortunately, loss of
response to biological agents is often observed in clinical
practice, ranging from 23 to 46 % after 12 months in CD
patients treated with infliximab or adalimumab [3]. The
mechanism underlying clinical exacerbations during
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biological treatment is not fully understood. The loss of
response has been associated with the development of
antibodies to anti-TNF-a agents and rapid drug clearance
[3, 4]. It was also postulated that some other pathways
involved in CD development may be responsible, for
example those associated with pro-inflammatory cytokines,
like IL-12, IL-17, and IL-23 [5–8].
Several blood parameters have been evaluated as
potential indicators of disease activity and predictors of the
risk of relapse in CD patients during biological treatment.
The most commonly used are the following: C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), white
blood cell (WBC) count, acid glycoprotein, platelet count,
albumin with fecal (calprotectin) and serologic markers [9].
Previous studies suggested that platelets might also be
involved in the pathogenesis of CD [10–12]. The mean
platelet volume (MPV) has been reported to be an inde-
pendent laboratory marker of clinical IBD disease activity.
It has been shown that decreased MPV correlates with
increased disease activity in patients with ulcerative colitis
(UC) and CD [12]. It was also demonstrated that treatment
with anti-TNF-a agents, such as infliximab, significantly
improves MPV in patients with inflammatory lesions in
rheumatoid arthritis (RA) [13]. In this study, we hypothe-
sized that MPV level may be a useful biomarker of sub-
clinical inflammation in patients with CD responding to
infliximab induction treatment and therefore may predict
maintenance or loss of response to further treatment. The
aim of the study was to establish whether MPV at baseline
and pre-infusion at week 14 are good predictors of sus-
tained response or remission after week 14 in CD patients
undergoing 52-week anti-TNF-a therapy with infliximab.
Methods
Patients
A retrospective study was conducted in 30 adult patients
with CD of Caucasian origin (22 men and 8 women; mean
age ± standard deviation 32.8 ± 8.7 years), who were
qualified for 52-week therapy with infliximab from January
2008 to March 2014 at the Department of Gastroenterology
of the Medical University of Lodz, Poland. The control
group comprised 15 individuals—students, staff, and
patients with dyspepsia or irritable bowel syndrome, and
was homogenous to the study group in terms of age, sex,
and body mass index (BMI). CD was diagnosed and con-
firmed according to clinical, radiological, endoscopic, and
histological criteria developed by the European Crohn’s
and Colitis Organisation (ECCO) [2]. The clinical state of
each patient was classified at designated time points
according to Crohn’s Disease Activity Index (CDAI),
which is a complex scoring system based on characteristic
clinical symptoms, such as the number of liquid stools,
severity of abdominal pain, general well-being, extrain-
testinal CD manifestations, abnormal abdominal mass, use
of loperamide or opiates for diarrhea, hematocrit, and body
weight [1, 2]. The CDAI is a validated clinical/laboratory
scoring system, used largely in trial settings to assess the
activity of disease and the response to treatment. Despite
limitations, the score has been widely used to evaluate drug
efficacy in CD over a 25-year period; secondly, and per-
haps more importantly, it reflects and correlates with
clinical assessment and patient well-being, which is the
general basis on which treatments for CD are currently
justified.
Inclusion criteria for biological therapy were exacerba-
tion of the underlying disease, CDAI over 300, and the
ineffectiveness of previously used non-biological therapies,
such as mesalazine, azathioprine, and corticosteroids. All
patients had endoscopic activity of intestinal lesions with
ulcers, seen at colonoscopy performed just prior to initia-
tion of infliximab therapy. All CD patients enrolled to
biological therapy received induction treatment with a
5 mg/kg infliximab infusion over 2 h at baseline and next
infusion at dose of 5 mg/kg at 2 and 6 weeks. The main-
tenance treatment was administered at a dose of infliximab
5 mg/kg every 8 weeks. A 1–2 day departure from the
scheme was allowed.
The CD patients enrolled in the study were in response
or clinical remission at week 14 (Scheme 1); in these
patients, infliximab induction had been effective and
maintenance treatment began. Response to anti-TNF-a
treatment was defined as a reduction in CDAI score by
C25 % and C70 points from baseline, and maintenance of
response as a sustained response at each visit after inflix-
imab induction treatment. Clinical remission of CD was
defined as a CDAI score of\150. If response or remission
was achieved at each visit after week 14, during the whole
52-week therapy, the patient was considered to have sus-
tained response or remission in 52-week therapy. Loss of
infliximab response after week 14 was defined as meeting
one of the following criteria: (1) a CDAI score of C175 and
an increase in CDAI score of C35 % and C70 points for at
least two following clinic visits (C21 days); (2) undergoing
CD-related surgery; and (3) crossover from scheduled
therapy to episodic retreatment. The clinical status of each
patient was assessed at each visit associated with drug
administration, at 0, 2, 6 weeks, and every 8 week during
maintenance treatment.
Current smokers, obese patients (BMI[ 25 kg/m2),
patients with a history of cardiovascular disease, pul-
monary and kidney disease, allergy, diabetes, lichen pla-
nus, psoriasis, atopic dermatitis and other autoimmune skin
lesions and those treated with anti-inflammatory drugs
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(except azathioprine and corticosteroids), antioxidants, or
statins, which can affect the inflammation process and
MPV [14–16], were excluded from the study.
Collection of Blood Samples and Blood Analysis
From all patients, 2 ml venous blood was taken into stan-
dardized tubes containing ethylenediaminetetraacetic acid
(EDTA) to determine MPV and white blood cell count
(WBC). In CD patients, blood samples for analysis were
obtained before initiation of 52-week infliximab therapy
and after induction treatment at week 14. Blood analysis
was performed within 2 h after collection using the same
automatic analyser. The adult normal reference range for
MPV is 7.4–10.4 fl and for WBC 4.5–10.3 9 109/l. Also,
2 ml blood samples were collected into serum tube and
CRP was determined using automatic devices (adult nor-
mal reference range for CRP:\0.5 mg/dl).
Statistical Analysis
The data were analyzed using the Statistica 10.0 software
(StatSoft, Inc., United States). Results were expressed as
mean ± standard deviation. Receiver operating character-
istic (ROC) curves were constructed for the MPV analysis,
and the areas under the ROC curves with 95 % CIs were
calculated and compared with each other. Optimal cutoff
values for MPV, used to discriminate between patients
with and without sustained response to infliximab, were
calculated by ROC curves. Sensitivity, specificity, and
positive and negative predictive values (PPV, NPV,
respectively) of the cutoff values and association were
analyzed. Shapiro–Wilk’s test was used to test the distri-
bution of the variables. Comparisons between groups were
performed using the Student’s t test (or nonparametric
Mann–Whitney U test) and Chi-square test. Correlations
were evaluated using the Pearson’s test or Spearman’s
rank correlation coefficient (r) test depending on normality
of distribution.
A p\ 0.05 was considered significant.
Ethical Considerations
The study was conducted in accordance with the ethical
principles of the 1975 Declaration of Helsinki and the
study protocol was approved by the Committee of
Bioethics of Medical University of Lodz.
Results
The baseline characteristics of all 30 CD patients who
underwent 52-week biological therapy with infliximab and
15 healthy controls are presented in Table 1. Nearly 50 %
(n = 15) of the CD patients enrolled in the study had ileo-
colonic disease. Laboratory tests revealed that CD patients
had significantly lower baseline MPV (10.25 ± 0.99 vs.
11.29 ± 1.08 fl; p = 0.003) and hematocrit (Ht) levels
(37.4 ± 6.4 vs. 43.6 ± 11.4 %; p = 0.025), as well as sig-
nificantly higher platelet counts (PLT) (329 ± 150 vs.
Response or clinical remission at week 14; reduction in CDAI score by ≥25% and ≥70 
points from baseline. Clinical remission of CD was defined as a CDAI score of <150. 
Inclusion criteria for biological therapy were exacerbation of the underlying disease, CDAI 
over 300 and the ineffectiveness of previously used non-biological therapies, such as 
mesalazine, azathioprine and corticosteroids. CD confirmed in colonoscopy specimens 






Loss of infliximab response after week 14: meeting one of the following 
criteria: (i) a CDAI score of ≥175 and an increase of CDAI score of ≥35% and 
≥70 points for at least two following clinic visits (≥21 days); (ii) undergoing 
CD-related surgery; (iii) crossover from scheduled therapy to episodic re-
treatment. 
n=15
Response or clinical remission at each visit 
after week 14 during 52 week treatment ; 
reduction in CDAI score by ≥25% and ≥70 
points from baseline. Clinical remission of CD 
was defined as a CDAI score of <150. 
n= 15
Exclusion criteria: current smokers, obese patients (BMI >25 kg/m2), patients 
with a history of cardiovascular disease, pulmonary and kidney disease, 
allergy, diabetes, lichen planus, psoriasis, atopic dermatitis and other 
autoimmune skin lesions and those treated with anti-inflammatory drugs 
(except azathioprine and corticosteroids), antioxidants, or statins, which can 
affect the inflammation process and MPV . 
n=  37
Scheme 1 The flow chart for patients’ enrollment in the study
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247 ± 48 9 103/ll; p = 0.049) compared with the healthy
control group. The study showed a negative correlation of
moderate strength in CD patients between baseline CDAI
and MPV (r = -0.522; p = 0.003; Fig. 1), and Ht
(r = -0.438; p = 0.015). There was no significant corre-
lation between the CDAI and CRP, WBC, and PLT levels
(r = 0.267; p = 0.153; r = 059; p = 0.757; r = 0.168;
p = 0.375; respectively). CRP levels in CD patient were
significantly increased at baseline compared with healthy
controls (19.7 ± 25.3 vs. 1.1 ± 0.8; p = 0.009). However,
seven CD patients (n = 7; 23.3 %) had persistent low CRP
levels (CPR level under 5 mg/dl) despite clinical and endo-
scopic disease activity.
In all CD patients, there was no significant association
between infliximab sustained response and gender
(p = 0.099) or age at diagnosis (31.3 ± 9.2 vs. 34.2 ± 8.6;
p = 0.385) (Table 2). No significant relationship was found
between location and response to infliximab (p = 0.507),
and disease duration (p = 0.410) (Table 2).
Baseline MPV and week 14 MPV levels in CD patients
were not influenced by perianal disease (p = 0.942 and
p = 0.721, respectively), disease location (p = 0.121 and
p = 0.224, respectively), or disease duration (p = 0.131
and p = 0.398, respectively).
Table 1 Baseline clinical
characteristics and laboratory
findings in the Crohn’s disease
(CD) patients enrolled to a
52-week infliximab therapy and
healthy controls
Crohn’s disease Control group p*
Subjects, n (%) 30 14 NA
Sex
Women, n (%) 8 (26.7 %) 5 (35.7 %) 0.540
Men, n (%) 22 (73.3 %) 9 (64.3 %)
Age, year 32.8 ± 8.7 33.0 ± 8.0 0.934
BMI, kg/m2 22.7 ± 2.5 23.1 ± 1.5 0.604
Duration of disease, year 5.9 ± 2.9 NA NA
Location of lesions, n (%)
Ileum lesions 2 (%) NA NA
Colon lesions 9 (%)
Ileum and colon lesions 19 (%)
Perianal lesions 14 (%)
CDAI, points 373.4 ± 50.7 NA NA
Corticosteroid history, n (%)
Never used 1 (3.3 %) NA NA
B1 year 3 (10.0 %)
[1 to B2 years 11 (36.7 %)
[2 years 15 (50.0 %)
Hematocrit, % 37.4 ± 6.4 43.6 ± 11.4 0.025
White blood cell count, 9103/ll 9.37 ± 2.70 6.11 ± 2.59 \0.001
Platelet count, 9103/ll 329 ± 150 247 ± 48 0.049
Mean platelet volume, fl 10.25 ± 0.99 11.29 ± 1.08 0.003
CRP, mg/dl 19.7 ± 25.3 1.1 ± 0.8 0.009
Data are presented as mean ± standard deviation or number (percentage)
BMI Body mass index, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein, NA not applicable
p*—statistical significance between CD patients and healthy control group
Fig. 1 Correlation between the mean platelet volume (MPV) level
and Crohn’s Disease Activity Index (CDAI) score (r = -0.52;
p = 0.003)
Dig Dis Sci (2016) 61:542–549 545
123
In the study, only patients with CD who responded or
achieved remission under infliximab induction treatment at
week 14 were enrolled. Fifteen (50.0 %) of these patients
have not reached a 1-year maintenance treatment without
loss of response (short-term response): eleven (37.0 %)
manifested clinical exacerbation of disease activity at
52-week maintenance treatment with infliximab (CDAI
score of C175 and an increase from the induction CDAI
score of C35 % and C70 points for at least two following
clinical visits), two (6.5 %) underwent surgery, and two
(6.5 %) had to crossover from scheduled therapy to epi-
sodic retreatment.
The CD patients with sustained response had signifi-
cantly higher MPV at week 14 compared with those who
lost response to maintenance infliximab treatment
(11.31 ± 1.16 vs. 10.19 ± 0.52 fl; p = 0.0019; Fig. 2).
Furthermore, the MPV at baseline in CD patients with
sustained response was higher than in the patients who
relapsed; however, the association between baseline MPV
and the maintenance of response was not significant
(10.53 ± 1.28 vs. 9.97 ± 0.48 fl; p = 0.1187). DMPV,
which signifies a change of MPV between baseline and
week 14, was lower in patients with loss of response to
infliximab versus patients with sustained response
(0.227 ± 0.392 vs. 0.780 ± 0.343 fl; p = 0.0003; Fig. 3).
ROC curves were constructed to assign optimal cutoff
values associated with sustained response to infliximab
maintenance treatment. Areas under curves were 0.82 for
MPV at week 14 and 0.92 for DMPV. The analysis showed
that MPV[ 10.3 fl at week 14 predicts sustained response to
infliximab treatment with 67 % sensitivity and 80 % speci-
ficity (Fig. 4). The negative predictive value (NPV) was
71 %.DMPV between baseline and week 14 higher than 0.4 fl
predicted sustained response during 52-week treatment with
87 % sensitivity and 93 % specificity; the NPV was 88 %.
At week 14, twenty (20/30) CD patients had
MPV C 10.3 fl and 65 % of them (13/20) had sustained
response to maintenance infliximab treatment. Ten (10/30)
CD patients had \10.3 fl and 20 % (2/10) had sustained
response to infliximab (p = 0.01; Fig. 5). Twenty-one (21/
30) CD patients hadC0.4 flDMPV (an increase in MPV value
between baseline and week 14) and 71 % of them (15/21) had
sustained response to infliximab. None of nine (9/30) CD
patients with\0.4 fl DMPV had sustained response to main-
tenance treatment (p = 0.0003). The ROC curves were also
constructed for Hct, CRP, PLT, and WBC at week 14; how-
ever, the results were insignificant (WBC AUC = 0.524; Hct
Table 2 Baseline clinical
characteristics in the Crohn’s
disease (CD) patients with and
without sustained response to
maintenance infliximab
treatment
Sustained response Loss of response p*
Subjects, n (%) 15 15 NA
Sex
Women, n (%) 2 (25 %) 6 (75 %) 0.099
Men, n (%) 13 (59 %) 9 (41 %)
Age at diagnosis, year 31.3 ± 9.2 34.2 ± 8.6 0.385
BMI, kg/m2 23.1 ± 3.1 22.4 ± 1.9 0.494
Duration of disease, year 5.4 ± 3.1 6.5 ± 2.8 0.410
Location of lesions, n (%)
Ileum lesions 1 (50 %) 1 (50 %) 0.510
Colon lesions 3 (33 %) 6 (67 %)
Ileum and colon lesions 11 (58 %) 8 (42 %)
Baseline CDAI, points 365.9 ± 49.9 381.0 ± 52.0 0.423
Data are presented as mean ± standard deviation or number (percentage)
BMI Body mass index, CDAI Crohn’s Disease Activity Index, NA not applicable
p*—statistical significance between sustained response and loss of response
Fig. 2 Difference between mean platelet volume (MPV) levels in
Crohn’s disease (CD) patients with sustained and lost response to
infliximab maintenance treatment (p = 0.0019)
546 Dig Dis Sci (2016) 61:542–549
123
AUC = 0.542; CRP AUC = 0.567; PLT AUC = 0.598;
compared to MPV at week 14 AUC = 0.818).
Discussion
We observed that higher MPV is a good indicator of a
sustained response to maintenance treatment during
52-week infliximab therapy. Observation of MPV during
induction treatment may become a useful tool in person-
alized therapy and result in better control of CD.
Infliximab, which is widely used in CD patients, effec-
tively controls clinical symptoms, maintains remission,
prevents relapses, improves quality of life, and reduces
mortality. Furthermore, most CD patients respond posi-
tively to infliximab and clinical response after induction of
remission is often achieved. Nevertheless, loss of response
in CD patients under maintenance treatment with inflix-
imab is still a common problem. Therefore, a predictor of
response to anti-TNF-a therapy is essential in clinical
practice [4, 15, 16].
MPV is an automated measurement of the average size of
platelets in whole blood that adds no extra cost or effort to a
full blood count. The relationship between MPV and
inflammatory process has been investigated [4, 7, 10, 11, 13,
17]. Currently, platelets with higher volume are considered
to be involved in the infiltration of tissues with inflammation
[11]. Also, b-thromboglobulin (b-TG) and platelet factor 4
(PF4), specific proteins discharged from platelet a-granules,
have been suggested to be markers of platelet activation and
influence platelet production [18]. Recent studies showed a
possible relationship between MPV and some inflammatory
diseases, such as acute appendicitis, chronic hepatitis B,
myocardial infarction, diabetes mellitus, RA, and IBD [17,
19, 20]. For IBD, increased count and low size of platelets, as
well as prothrombotic state were observed [10]. Also,
increased b-TG and PF4 plasma levels have been reported
[18]. Of note, a decreased MPV was evidenced as an
important and useful biomarker of CD exacerbations [11].
The possible explanation for this phenomenon is that the
excessive production of pro-inflammatory cytokines and
acute-phase reactants may suppress the size of the platelets
by interfering with megakaryopoiesis, which is followed by
the release of small size platelets from the bone marrow [4].
Fig. 3 Relationship between D mean platelet volume (DMPV) levels
(difference between baseline MPV levels and at week 14) in Crohn’s
disease (CD) patients with sustained and lost response to infliximab
maintenance treatment (p = 0.0003)
Fig. 4 Receiver operating characteristic curve for mean platelet
volume (MPV) levels at week 14 and the loss of response to
infliximab maintenance treatment in Crohn’s disease (CD) patients
during a 52-week therapy
Fig. 5 Association between sustained response to infliximab
52-week maintenance therapy and mean platelet volume (MPV)
levels at week 14 in Crohn’s disease (CD) patients
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Another possible explanation of the decreased size of cir-
culating platelets in exacerbation of CD relates to the
intensive infiltration of large platelets at sites of inflamma-
tion. It is known that large platelets are more active in
releasing a variety of pro-inflammatory and thrombotic
agents than smaller size platelets, and their circulating count
may thus be decreased by the consumption by peripheral
tissues during the acute stage of inflammation [13]. In line
with these hypotheses, Gasparyan et al. [10] suggested that
microaggregates and microinfarction of mesenteric vessels
unveil a potential role of platelets as pro-inflammatory cells
in pathogenesis of CD. Others showed that platelets and their
MPV are associated with thromboembolic risk in IBD
patients and may play a role in pathogenesis of inflammation
in the intestine wall. In some studies, a significant negative
correlation between MPV and disease activity was observed
[15], and it was suggested that a decreased MPV is an
independent marker of increased disease activity in CD [21].
Similar results were demonstrated in clinical observations
[20]. In our study, a significantly lower MPV was observed in
CD patients than in healthy controls, which supports the
hypothesis about the possible role of MPV in monitoring
disease status. We also observed that the clinical activity of
CD, expressed on CDAI scale, at time of enrollment to
infliximab therapy significantly correlates with MPV.
Anti-TNF-a drugs are used in the treatment of other
immunological disorders, such as RA. Gasparyan et al. [13]
suggested that MPV increases during anti-TNF-a therapy
and may be a good predictor of clinical response to biological
treatment in RA patients. However, to the best of our
knowledge, earlier studies have not analyzed MPV as a
possible predictor of sustained response to biological therapy
with infliximab in CD patients. Here, we observed that higher
MPV at week 14 in clinical responders to infliximab induc-
tion treatment is a good indicator of a sustained response to
maintenance treatment during 52-week therapy. Further-
more, CD patients with a[0.4 fl increase in MPV after an
induction infliximab treatment (between week 0 and 14)
were more likely to maintain response and remission. Since
MPV[ 10.3 fl at week 14 predicts sustained response with
67 % sensitivity and 80 % specificity, and DMPV (differ-
ence between baseline and week 14) higher than 0.4 fl pre-
dicts sustained response with 87 % sensitivity and 93 %
specificity, we suggest for the first time that the MPV could
be a useful predictor in medical practice.
Conclusion
In conclusion, our study showed that MPV may be a useful
biomarker predicting a sustained response in the 52-week
treatment in CD patients receiving infliximab. We suggest
that MPV, as an easily accessible biomarker, will allow
clinicians to select the most appropriate individual treat-
ment. In case of possible loss of response, physicians will
be able to increase the dose of anti-TNF-a antibodies,
change drugs or consider other treatments (i.e., antibodies
against cell adhesion molecules).
This pilot study was performed on a small group of IBD
patients. Further studies are warranted to confirm our
observations on the predicting role of MPV and to establish
the cutoff points in a larger cohort. Also, the possible
application of this parameter in CD patients treated with
other anti-TNF-a agents needs verification.
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